

Members of Xbrane's management team sell shares to pay taxes but remain dedicated and long-term employees and shareholders

Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) announces that members of Xbrane's management team have sold shares to pay taxes that arose in connection with the allotment of shares under a long term incentive program. Martin Åmark has sold 27,000 shares and has a remaining ownership of 171,490 shares. Siavash Bashiri has sold 10,179 shares and has a remaining ownership of 120,714 shares.

"The sale is made solely to pay taxes that arose due to the allotment of shares from our long term incentive program and our remaining holdings in Xbrane are still by far our largest private financial investments. Our commitment and strong belief in Xbrane's future prospects remains," says Martin Åmark, CEO of Xbrane

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Members of Xbrane's management team sell shares to pay taxes but remain dedicated and long-term employees and shareholders](#)